Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod In Japan
Zacks Investment Research | Nov 24, 2019 09:03PM ET
Myriad Genetics, Inc. (NASDAQ:MYGN) recently announced that the Japanese Ministry of Health, Labour and Welfare has approved the company’s BRACAnalysis Diagnostic System for HBOC (Hereditary breast-ovarian cancer syndromes) risk assessment. Following this nod, physicians in Japan can now identify if the patients with breast cancer have HBOC syndrome and accordingly, qualify for additional medical management.
BRACAnalysis is a genetic test that identifies germline BRCA1 or BRCA2 gene mutations. We encouragingly note that BRACAnalysis is the first and the only diagnostic test for a PARP inhibitor to be approved in Japan.
The latest approval of BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.
Moreover, Myriad Genetics entered into an exclusive partnership with SRL Inc. to market BRACAnalysis in Japan. This subsidiary of Miraca Group is one of the largest laboratory service providers in Japan.
BRACAnalysis’ Earlier Breakthroughs in Japan
In February 2019, BRACAnalysis was approved in Japan as a companion diagnostic for Lynparza (olaparib) pertaining to women with ovarian cancer.
In March 2018, BRACAnalysis was approved as a companion diagnostic for Lynparza in relation to patients with metastatic inoperable or recurrent breast cancer. Post this nod, physicians in Japan were authorized to prescribe BRACAnalysis for patients diagnosed with metastatic breast cancer to detect if they carry germline BRCA1 or BRCA2 gene mutations.
Fortifying its foothold internationally, the company is steadily receiving a satisfactory response to its BRACAnalysis CDx in Japan for addressing metastatic breast cancer. In this regard, it secured a Japanese approval for BRACAnalysis CDx as the companion diagnostic to treat first-line ovarian cancer with olaparib.
Market Potential
The company is optimistic about the scope of BRACAnalysis in Japan considering that every year, roughly 22,000 cancer patients across the Land of the Rising Sun are eligible for companion diagnostic testing.
This promising data indicates that this latest approval is timely and a strategic fit to play in favor of Myriad Genetics.
Share Price Performance
Myriad Genetics has been gaining investors’ confidence on consistently positive results. Over the past three months, shares of the company have outperformed its Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.